Biomedical subjects
Publications and source records attributed to J C Callaghan.
Hypothermic asanguineous perfusion has been used to arrest 170 hearts at the beginning of 1/2 to 2 hours of intraoperative coronary ischemia. This method of producing cardioplegia has facilitated valve replacement and coronary artery bypass operations. Inadequate myocardial protection has not been experienced since we began using this method of arresting the heart for cardiac operations.
The experience with tricuspid valve replacement (TVR) with seven different prostheses, alone or combined with replacement of other valves, in 73 patients (64 rheumatic and nine nonrheumatic) between 1964 and March, 1975, at the University of Alberta Hospital has been reviewed. Early and late mortality rates in rheumatic patients were 41 and 23 percent, respectively (36 percent being alive after a mean of 5.6 years), compared to 33 and 11 percent, respectively, in the nonrheumatic patients (56 percent being alive after a mean of 2 years). Of all survivors, 88 percent were functionally improved. Among the rheumatic patients: (1) 88 percent had organic tricuspid disease; (2) of the 39 patients with tricuspid insufficiency who underwent corrective mitral surgery 7 years before TVR, the tricuspid insufficiency had progressed over the 7 years; (3) the number of patients with tricuspid insufficiency had increased (39 versus 59) over the same 7 year period; (4) a high early mortality rate was encountered in those who were preoperatively in New York Heart Association (N.Y.H.A.) Class IV, or who had cardiomegaly, or pulmonary hypertension, or poor ventricular function, or organic disease, or reoperation; (5) the percentages of survivors with different prostheses were: Starr-Edwards, 31 percent; Beall-Surgitool, 14 percent; Kay-Shiley, 46 percent, Björk-Shiley, 50 percent; Lillehei-Kaster, 100 percent; Cutter-Smeloff and Wada-Cutter, nil. Among the nonrheumatic patients, two with the Cutter-Smeloff, two with the Beall-Surgitool, and one with the Lillehei-Kaster were alive after 14, 37, and 15 months, respectively. Among all survivors of TVR, late thrombus and pannus developed on both ball and disc prostheses (Starr-Edwards, two; Cutter-Smeloff, one; Lillehei-Kaster, one). These findings suggest that TVR should be performed earlier in rheumatic patients to reduce the operative mortality rate and that the Lillehei-Kaster prosthesis is probably most suitable for TVR.
Neither the role of surgery in Ebstein's anaomaly nor the surgical procedure of choice for its correction are clearly defined. Whether or not the artrialized right ventricle, which plays a major role in the functional abnormalities, should be obliterated in all cases remains unresolved. Of the 26 patients with Ebstein's anomaly seen at the University Hospital between 1953 and 1975, four were treated surgically at this center. All had closure of the atrial septal defect, reconstruction of a tricuspid annulus in the normal position, and insertion of a tricuspid prosthesis and an epicardial ventricular pacemaker. The two patients who also had the atrialized chamber obliterated improved dramatically. Thus, obliteration of the atrialized right ventricle appears to be associated with a better operative result.
A case of accidental pneumatic rupture of the thoracic esophagus in a 6-year-old boy is reported. Early operation with transthoracic esophageal repair resulted in survival of the patient, and follow-up at 18 months has demonstrated normal esophageal function and anatomy. A search of the literature has yielded 11 similar cases.
A melanotic malignant schwannoma of the right atrium occurring in a 14-year-old girl is described. No previous such tumors in this location have been reported.
In 111 patients whose diseases mitral valve was replaced with a ball-valve prosthesis the actuarial survival rate, including the hospital mortality of 10.8%, was 66% after 5 years and 59% after 8 years of follow-up. This suggests that in patients with moderate or severe symptoms due to mitral valve disease, replacing the valve can prolong life. However, in patients with no cardiac symptoms or with sinus rhythm and mild symptoms, it is doubtful that mitral valve replacement can prolong life, for the prognosis in these patients is favourable without operation.
Forty-eight radial artery grafts and 22 saphenous vein grafts in 37 patients undergoing coronary bypass procedures were studied early postoperatively. Most of the saphenous vein grafts were patent, but one-half of the radial artery grafts were occluded. Failure of the radial artery grafts could not be attributed to unfavorable runoff in the recipient vessels. Radial arteries carrying higher flows and those to vessels having more severe degrees of proximal stenosis occluded with a higher frequency. The radial artery should not be used for coronary bypass.
The long-term prognosis of 187 consecutive patients who received single aortic valve replacement using Smeloff-Cutter prosthesis was studied. Of the 163 patients who survived the operation, a long-term follow-up (up to eight years) was obtained in 153 patients (95%). A total of 34 patients (22%) died during the follow-up period. Including the hospital mortality, the actuarial survival rate of our patients with Smeloff-Cutter prosthesis was 0.69 after the fifth year and 0.611 after the eighth year of follow-up. This is similar to the actuarial survival rate of patients with Starr-Edwards prosthesis but it appears significantly better than the expected survival rate of symptomatic patients with aortic stenosis treated without surgery. Thus, this result supports the contention that aortic valve surgery in properly selected patients can prolong life expectancy in addition to relieving symptoms in patients with aortic valve disease. The majority of surviving patients reported to have improved (88%) since the operation and to be symptom free (82%).
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.